- In March 2023, SolasCure successfully closed a GBP 10.9 million (USD 13.3 million) Series B funding round, aimed at enhancing wound care innovation. This investment will support the continued development of the Aurase Wound Gel and advance Phase II clinical trials for pioneering enzymatic wound debriding treatments, positioning the company to lead in wound care solutions
- In February 2023, SERDA Therapeutics filed an Investigational New Drug Application (IND) with the United States FDA for its lead product, SN514 hydrogel. This enzymatic wound debriding agent aims to revolutionize wound healing by providing an advanced solution for tissue debridement, positioning SERDA Therapeutics as a key player in the wound care market's growth
- In November 2020, Gunze Limited introduced an ultrasonic wound debridement device, marking a significant technological advancement in the wound care industry. This device enhances the efficiency of wound debridement by using ultrasonic waves to remove dead tissue, promoting faster healing and reducing infection risk. Gunze's innovation is set to contribute to the industry's expansion in the coming years
